Literature DB >> 15876922

Health burden of pertussis in infants and children.

David P Greenberg1, Carl-Heinz Wirsing von König, Ulrich Heininger.   

Abstract

In countries with high rates of vaccination against pertussis, the incidence of this disease has decreased dramatically compared with the prevaccine era. However, pertussis still occurs in these countries, and severe morbidity and mortality are greatest among infants, particularly those who are unimmunized or incompletely immunized. Pertussis in older children and adults is perceived by many as being a mild disease, but it is a significant health burden in persons of all ages. Infants with pertussis experience the highest rates of hospitalization, complications and death. Severe complications include pneumonia, encephalopathy and meningoencephalitis. In addition, infants may experience weight loss, bronchitis, otitis media, apnea, cyanosis, inguinal hernia and rectal prolapse. It is essential to explore methods to prevent disease transmission to infants in the months before they complete their primary immunization series. The Global Pertussis Initiative was established to assess the true health burden of pertussis in infants and to suggest strategies to combat transmission and infection with Bordetella pertussis, which remains a significant public health concern.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876922     DOI: 10.1097/01.inf.0000160911.65632.e1

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

1.  Hemolytic uremic syndrome caused by Bordetella pertussis infection.

Authors:  Swasti Chaturvedi; Christoph Licht; Valerie Langlois
Journal:  Pediatr Nephrol       Date:  2010-02-10       Impact factor: 3.714

2.  Protecting newborns by immunizing family members in a hospital-based vaccine clinic: a successful Tdap cocooning program during the 2010 California pertussis epidemic.

Authors:  Elizabeth Rosenblum; Sarah McBane; Wendy Wang; Mark Sawyer
Journal:  Public Health Rep       Date:  2014-05       Impact factor: 2.792

3.  T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.

Authors:  Pascal Feunou Feunou; Julie Bertout; Camille Locht
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

4.  Serendipitous discovery of an immunoglobulin-binding autotransporter in Bordetella species.

Authors:  Corinne L Williams; Robert Haines; Peggy A Cotter
Journal:  Infect Immun       Date:  2008-04-21       Impact factor: 3.441

5.  Bordetella bronchiseptica responses to physiological reactive nitrogen and oxygen stresses.

Authors:  Anders Omsland; Katrina M Miranda; Richard L Friedman; Scott Boitano
Journal:  FEMS Microbiol Lett       Date:  2008-05-06       Impact factor: 2.742

6.  Detection of Bordetella pertussis in Infants Suspected to have Whooping Cough.

Authors:  Massoud Hajia; Mohammad Rahbar; Fatemeh Fallah; Nooshafarin Safadel
Journal:  Open Respir Med J       Date:  2012-06-15

7.  The causal effect of childhood measles vaccination on educational attainment: A mother fixed-effects study in rural South Africa.

Authors:  Tobenna D Anekwe; Marie-Louise Newell; Frank Tanser; Deenan Pillay; Till Bärnighausen
Journal:  Vaccine       Date:  2015-04-30       Impact factor: 3.641

8.  Infant pertussis and household transmission in Korea.

Authors:  Hyo Jin Kwon; Sook Kyung Yum; Ui Yoon Choi; Soo Young Lee; Jong Hyun Kim; Jin Han Kang
Journal:  J Korean Med Sci       Date:  2012-12-07       Impact factor: 2.153

9.  The epidemiology of pertussis in Germany: past and present.

Authors:  Wiebke Hellenbrand; Dietmar Beier; Evelin Jensen; Martina Littmann; Christiane Meyer; Hanna Oppermann; Carl-Heinz Wirsing von König; Sabine Reiter
Journal:  BMC Infect Dis       Date:  2009-02-25       Impact factor: 3.090

10.  Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.

Authors:  Shane Byrne; Andrew T Slack
Journal:  BMC Infect Dis       Date:  2006-03-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.